Skip to content

The Policy Vault

Methodology Why Contact

Coverage / Blue Cross Blue Shield of Oklahoma / Xeljanz XR (tofacitinib extended release) / Contraindicated as concomitant therapy

Xeljanz XR (tofacitinib extended release) — Blue Cross Blue Shield of Oklahoma

Contraindicated as concomitant therapy

Initial criteria

Agents listed are NOT to be used concomitantly.

Provenance

View official policy PDF

Plan: Blue Cross Blue Shield of Oklahoma
Drug: Xeljanz XR (tofacitinib extended release)
Indication: Contraindicated as concomitant therapy
Last seen: 2025-10-23
Hash: 5035471898b8…

Disclaimer: Educational only. Coverage varies by employer group and formulary. Always verify with the plan.

Consult

Curious about trends across plans?

I can walk you through how this policy compares and share data-backed patterns. Short call, straight answers.

Email to start a quick consult What I cover (overview)

No commitments—just a brief conversation to see if it’s helpful.

The Policy Vault

Structured prior authorization and step-therapy criteria for commercial health plans. Built by pharmacists for healthcare professionals.

Disclaimer: Educational use only. Coverage varies by employer group and formulary. Always verify with the plan.

Product

Coverage Directory
Why Policy Vault
Methodology

Company

Contact
Press
Support

© 2025 The Policy Vault. Data sourced from official health plan documents.